Andrew Nixon, Boehringer Ingelheim's global head of biotherapeutics discovery

Boehringer In­gel­heim and IBM team up to make an­ti­bod­ies with gen­er­a­tive AI

Boehringer In­gel­heim is the lat­est drug­mak­er turn­ing to gen­er­a­tive AI for help in mak­ing med­i­cines. On Tues­day, the Ger­man phar­ma gi­ant an­nounced a part­ner­ship with IBM to cre­ate an­ti­bod­ies us­ing the com­put­er com­pa­ny’s ar­ti­fi­cial in­tel­li­gence tech­nol­o­gy.

The com­pa­nies, each among the old­est in their re­spec­tive in­dus­tries, are not mere­ly jump­ing aboard the lat­est trend. Boehringer told End­points News that the part­ner­ship was years in the mak­ing. It sees us­ing AI for drug de­sign as a long-term in­vest­ment, and not nec­es­sar­i­ly one that will flood its pipeline with drugs any­time soon.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA